HCPLive Network

Sleep Restriction Affects Respiratory, Vascular Control

FRIDAY, April 26 (HealthDay News) -- Partial sleep deprivation leads to less healthy vascular function and impaired breathing control, according to a study presented at Experimental Biology 2013, held from April 20 to 24 in Boston.

Keith Pugh, from the University of Birmingham, in the United Kingdom, and colleagues assessed chemosensitivity and endothelial function (measured by flow-mediated dilation) in eight participants assigned to either a sleep restriction protocol consisting of a baseline night of eight hours sleep, followed by three nights of four hours sleep, or a control protocol consisting of the same initial night followed by three nights of 10 hours of sleep opportunity.

The researchers found that, in the sleep restriction group, central chemosensitivity increased by 51.6 ± 9.4 percent after the second night of sleep restriction but returned to baseline after the third night. Central chemosensitivity remained unchanged in the control group. There was no difference in peripheral chemosensitivity between the two protocols. After the second night of sleep restriction, endothelial function decreased by 46.7 ± 1.6 percent but recovered after the third night. The control group did not experience changes in endothelial function.

"If acute sleep loss occurs repetitively over a long period of time, then vascular health could be compromised further and eventually mediate the development of cardiovascular disease," Pugh said in a statement.

Press Release
More Information

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Researchers assessed the effect of seizure status and severity, medication use, mental health indicators, parental support, and other factors on self-reported quality of life in children with epilepsy.
Complication rates are similar for single-level anterior cervical discectomy and fusions, whether the procedure is performed by a neurosurgeon or orthopedic surgeon, according to a study published in the Sept. 15 issue of Spine.
The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.
More Reading